证券代码：688656 证券简称：浩欧博 公告编号：2025-064 江苏浩欧博生物医药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 10 日（星期一）至 11 月 14 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （jshob@hob-biotech.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 17 日（星期一） 下午 14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成 ...

江苏浩欧博生物医药股份有限公司（688656） 2025 年第四次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司（688656） 2025 年第四次临时股东大会会议资料 2025 年第四次临时股东大会会议须知 江苏浩欧博生物医药股份有限公司（688656） 2025 年第四次临时股东大会会议资料 目录 | 2025 | 年第四次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第四次临时股东大会会议议程 | 4 | | 2025 | 年第四次临时股东大会会议议案 | 6 | | | 议案一： | 6 | | | 关于取消监事会、修订《公司章程》并办理工商变更登记的议案 | 6 | | | 议案二： | 7 | | | 关于修订及制定公司部分治理制度的议案 | 7 | 1 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》《上市公司股东会规则》以及《江苏浩欧博生物医药股份 有限公司章程》（以下简称"《公司章程》"）、 ...

Market Overview - The medical device sector increased by 0.64% on November 5, with Haooubo leading the gains [1] - The Shanghai Composite Index closed at 3969.25, up 0.23%, while the Shenzhen Component Index closed at 13223.56, up 0.37% [1] Top Gainers in Medical Device Sector - Haooubo (688656) closed at 190.35, up 12.63% with a trading volume of 20,900 [1] - Jigaodafang (600807) closed at 3.59, up 5.59% with a trading volume of 574,800 [1] - Zhendemedical (603301) closed at 99.94, up 5.54% with a trading volume of 204,900 [1] - Huitaimedical (688617) closed at 290.33, up 5.42% with a trading volume of 14,700 [1] - Tianyimedical (301097) closed at 58.80, up 5.00% with a trading volume of 37,500 [1] Top Losers in Medical Device Sector - Weigao Blood Purification (603014) closed at 44.68, down 3.98% with a trading volume of 123,100 [2] - Xiangsheng Medical (688358) closed at 35.10, down 2.34% with a trading volume of 25,100 [2] - Weisi Medical (688580) closed at 50.93, down 2.28% with a trading volume of 13,700 [2] Capital Flow Analysis - The medical device sector saw a net inflow of 146 million yuan from institutional investors and 141 million yuan from retail investors, while retail investors experienced a net outflow of 287 million yuan [2] - Zhendemedical (603301) had a net inflow of 169 million yuan from institutional investors, while retail investors saw a net outflow of 153 million yuan [3] - Haooubo (688656) had a net inflow of 46.95 million yuan from institutional investors, with retail investors experiencing a net outflow of 514,420 yuan [3]

Investment Rating - The report maintains an "Accumulate" rating for the company [5] Core Insights - The company reported a revenue of 292 million yuan for the first three quarters of 2025, a year-on-year decline of 4.84%, while the net profit attributable to shareholders was 26 million yuan, down 1.41% year-on-year. However, in Q3 2025, the company achieved a revenue of 103 million yuan, a slight decline of 1.64% year-on-year, but the net profit increased significantly by 113.01% to 14.02 million yuan [1][2] - The company has made progress in its desensitization drug business, with successful completion of the first batch of subject administration in the Phase III clinical trial of the MM09 sublingual spray in collaboration with Inmunotek [3] - The company has received NCRC certification for its self-immune diagnostic capabilities, achieving full scores in all 46 projects it participated in, showcasing its expertise in the self-immune diagnostic field [2][3] Financial Performance Summary - For Q3 2025, the company's sales expense ratio was 22.94%, down 0.93 percentage points year-on-year; management expense ratio was 17.04%, down 4.64 percentage points year-on-year; and financial expense ratio was 0.44%, down 0.10 percentage points year-on-year [2] - The company’s R&D expenses for Q3 2025 were 12 million yuan, a year-on-year increase of 4.85%, accounting for 11.60% of revenue [2] - The company’s projected net profits for 2025-2027 have been adjusted to 36 million, 47 million, and 60 million yuan respectively, reflecting a downward revision of 3%, 6%, and 6% from previous estimates [3] Valuation Metrics - The current price corresponds to a PE ratio of 291 for 2025, 222 for 2026, and 173 for 2027 [3][4] - The company is positioned as a leading player in the domestic allergy testing and self-immune testing sectors, with expectations for growth driven by the integration of allergy diagnosis and treatment [3]

Core Insights - The company reported a decline in revenue and net profit for the first three quarters of 2025, with total revenue at 292 million yuan, down 4.8% year-on-year, and net profit attributable to shareholders at 26.19 million yuan, down 1.4% [1] - The third quarter showed a slight decrease in revenue but a significant increase in net profit, with revenue at 103 million yuan, down 1.6% year-on-year, while net profit rose 113% to 14.02 million yuan [1] - The company's total assets decreased by 6.5% year-on-year to 965 million yuan, while net assets attributable to shareholders increased by 2.1% to 829 million yuan [1] Financial Performance - Total revenue for the first three quarters was 292 million yuan, a decrease of 4.8% year-on-year [1] - Net profit attributable to shareholders for the same period was 26.19 million yuan, down 1.4% [1] - The net profit for the third quarter was 14.02 million yuan, an increase of 113% year-on-year [1] - The company reported a net cash flow from operating activities of 57.67 million yuan, down 24.5% year-on-year [1] Earnings Per Share - The fully diluted EPS for the first three quarters was 0.4126 yuan [1] - The EPS for the third quarter was 0.2209 yuan [1] Research and Development - The company's total R&D expenditure was 11.89 million yuan, accounting for 11.6% of total revenue [1]

Group 1 - The core point of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a stock price increase of 5.2%, reaching 156.91 CNY per share, with a total market capitalization of 9.961 billion CNY [1] - The company specializes in the research, production, and sales of in vitro diagnostic reagents, with 89.46% of its revenue coming from reagent sales [1] - The company was founded on June 8, 2009, and went public on January 13, 2021 [1] Group 2 - According to data, a fund under China Merchants Fund holds Haobio as its ninth largest position, with a total of 10,700 shares, representing 4.31% of the fund's net value [2] - The fund, named China Merchants Growth Pioneer Stock A, has seen a year-to-date return of 32.24% and a one-year return of 20.72% [2] - The fund manager, Mei Mei, has been in the position for 280 days, with the best return during this period being 37.41% [2]

Group 1 - The core viewpoint of the news is that Haooubo (688656.SH) has reported its Q3 2025 results, highlighting significant institutional investor holdings [1] - As of October 29, 2025, a total of 11 institutional investors hold shares in Haooubo, with a combined holding of 44.599 million shares, representing 70.26% of the total share capital [1] - The top ten institutional investors account for 70.24% of the total shares, with a decrease of 2.86 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely the China Merchants Growth Pioneer Stock A, has reduced its holdings slightly compared to the previous quarter [2] - Three new public funds have been disclosed this quarter, including Huaan Medical Biotechnology Stock Initiation A, Industrial Bank Healthcare A, and Huaan Flexible Allocation Mixed Initiation A [2] - A total of 129 public funds have not been disclosed this quarter, including notable funds such as Jiashi Environmental Protection Low Carbon Stock and CITIC Construction Investment Medical Reform A [2]

Core Viewpoint - The company, Jiangsu Haooubo Biopharmaceutical Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, with no significant omissions or misleading statements [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][7]. - The report includes major accounting data and financial indicators, although specific figures are not detailed in the provided text [3]. - The company has confirmed that there were no significant changes in the financial indicators compared to the previous period [4][6]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders are disclosed, with a specific mention of the repurchase account holding 801,314 shares, accounting for 1.26% of the total share capital [4][5]. Other Important Information - There are no additional reminders or significant operational updates regarding the company's performance during the reporting period [6].

Core Viewpoint - The company, Haobo (688656.SH), reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - Total operating revenue for the first three quarters reached 292 million yuan, representing a year-on-year decrease of 4.84% [1] - Net profit attributable to shareholders was 26.19 million yuan, down 1.41% year-on-year [1] - Basic earnings per share stood at 0.42 yuan [1]

Core Viewpoint - The company announced the election of Dong Shengnan as the employee representative director for its third board of directors [1] Company Summary - The announcement was made on the evening of October 29 [1]